Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On January 10, 2022, Entasis Therapeutics Holdings Inc. (the "Company") accepted the resignation of Michael Gutch, our Chief Financial Officer and Chief Business Officer. Dr. Gutch will continue to serve as our Chief Financial Officer and Chief Business Officer until February 24, 2022, on which date his employment with the Company shall terminate.

Dr. Gutch has indicated to the Company that his resignation is not the result of any dispute or disagreement with the Company.


                                       2

© Edgar Online, source Glimpses